Open access
108
Views
22
CrossRef citations to date
0
Altmetric
Original Research
Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective
George Dranitsaris1 Augmentium Pharma Consulting Inc., Toronto, ON, CanadaCorrespondence[email protected]
, Bo Yu2 Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China
, Jennifer King3 Celgene Corporation, Summit, NJ, USA
, Satyin Kaura3 Celgene Corporation, Summit, NJ, USA
& Adams Zhang3 Celgene Corporation, Summit, NJ, USA
Pages 249-256
|
Published online: 12 May 2015
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.